| pubmed-article:8126143 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8126143 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:8126143 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:8126143 | lifeskim:mentions | umls-concept:C0038720 | lld:lifeskim |
| pubmed-article:8126143 | lifeskim:mentions | umls-concept:C0870883 | lld:lifeskim |
| pubmed-article:8126143 | lifeskim:mentions | umls-concept:C0205164 | lld:lifeskim |
| pubmed-article:8126143 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8126143 | pubmed:dateCreated | 1994-4-12 | lld:pubmed |
| pubmed-article:8126143 | pubmed:abstractText | Previous studies have suggested that T3 metabolism relies more on nondeiodinative conjugation than on direct deiodinative degradation for its disposal in man. To better define this process, tracer T3 kinetic studies were performed in five euthyroid subjects before and after iopanoic acid (IA) administration to selectively impair T3 deiodinative disposal. Both a low IA (0.5-g load, followed by 0.5 g/day for 7 days) and a high IA (3.0-g load, followed by 3.0 g/day for 7 days) dosing schedule were employed to achieve varying levels of deiodinase inhibition. Additionally, the high IA dose was repeated with simultaneous oral T3 administration (100 micrograms daily) to normalize serum T3 levels that were reduced by IA-induced inhibition of T4 to T3 conversion. The results demonstrated that baseline serum T3 (2.3 +/- 0.1 nmol/L) and T3/T4 (1.9 +/- 0.1 x 10(-2)) values were significantly reduced by both the low IA (1.5 +/- 0.1 nmol/L and 1.2 +/- 0.1 x 10(-2), respectively) and the high IA (1.5 +/- 0.1 nmol/L and 0.9 +/- 0.2 x 10(-2), respectively) dosing schedule and that the addition of oral T3 to the high IA regimen restored both the T3 and T3/T4 levels to near-normal values (2.9 +/- 0.3 nmol/L and 1.7 +/- 0.2 x 10(-2), respectively). Low IA also significantly decreased T3 clearance (30 +/- 4 to 18 +/- 2 L/day; P < 0.005) and fractional urinary tracer recovery (70 +/- 3% to 37 +/- 4%; P < 0.005), whereas high IA produced only a minimal further reduction in clearance (16 +/- 2 L/day; P < 0.01) and urinary tracer recovery (32 +/- 3%; P < 0.05). Surprisingly, oral administration of T3 to the high IA regimen significantly increased T3 clearance (23 +/- 4 L/day; P < 0.01) without changing urinary tracer recovery (34 +/- 5%) compared to the effects of high IA alone. Evaluation of the urinary T3 metabolite pattern demonstrated that the major products of T3 metabolism were T3 sulfate and 3,3-diiodothyronine sulfate. These observations confirm previous results suggesting that the majority of nondeiodinative T3 disposal occurs via T3 sulfate formation. The additional finding that such nondeiodinative disposal may also be influenced by the circulating T3 level leads us to propose that sulfotransferase enzyme systems may play an important role in regulating the prereceptor availability of this ligand. | lld:pubmed |
| pubmed-article:8126143 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8126143 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8126143 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8126143 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8126143 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8126143 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:8126143 | pubmed:author | pubmed-author:NicoloffJ TJT | lld:pubmed |
| pubmed-article:8126143 | pubmed:author | pubmed-author:LoPrestiJ SJS | lld:pubmed |
| pubmed-article:8126143 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8126143 | pubmed:volume | 78 | lld:pubmed |
| pubmed-article:8126143 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8126143 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8126143 | pubmed:pagination | 688-92 | lld:pubmed |
| pubmed-article:8126143 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:meshHeading | pubmed-meshheading:8126143-... | lld:pubmed |
| pubmed-article:8126143 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8126143 | pubmed:articleTitle | 3,5,3'-Triiodothyronine (T3) sulfate: a major metabolite in T3 metabolism in man. | lld:pubmed |
| pubmed-article:8126143 | pubmed:affiliation | Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033. | lld:pubmed |
| pubmed-article:8126143 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8126143 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8126143 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8126143 | lld:pubmed |
